Full text is available at the source.
Abstract
GLP-1 medicines may reduce cancer incidence among individuals with type 2 diabetes and obesity.
- GLP-1 medicines are associated with reduced food intake, body weight, and insulin resistance.
- These medicines may improve inflammation levels, contributing to better health outcomes.
- Evidence suggests that GLP-1 medicines could suppress tumor development through both weight loss-dependent and weight loss-independent mechanisms.
- Data from trials and registries indicate a potential link between GLP-1 medicines and lower rates of obesity-related cancer.
Simplified